Physician profile
Albert Lo
NPI 1396730388
$5,391.32
in general payments reported to CMS, 2019-2025
16 companies · $2,131 in 2025
The $2,131 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $705 · 2020: $113 · 2021: $208 · 2022: $405 · 2023: $932 · 2024: $897 · 2025: $2,131.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,851 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,851.14 |
| Education | $109.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $954.66 | 2020-2025 | Caplyta |
| Alkermes, INC. | $667.90 | 2021-2025 | Aristada, Lybalvi, Aristada Initio |
| Otsuka America Pharmaceutical, INC. | $616.42 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| E.R. Squibb & Sons, L.L.C. | $572.13 | 2024-2025 | Cobenfy |
| Abbvie INC. | $444.13 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $441.47 | 2022-2025 | Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $421.07 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Neurocrine Biosciences, INC. | $293.02 | 2019-2025 | Ingrezza |
| Axsome Therapeutics, INC. | $283.31 | 2023-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $166.25 | 2019-2023 | Trintellix |
| Lundbeck LLC | $156.64 | 2019-2025 | Abilify Asimtufii |
| Ironshore Pharmaceuticals INC. | $115.71 | 2019 | |
| Supernus Pharmaceuticals, INC. | $113.73 | 2024 | Qelbree |
| Indivior INC. | $93.27 | 2022-2023 | Perseris |
| Allergan, INC. | $27.81 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $23.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Albert Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.